CME trades 10.4% below Wall Street's consensus target of $299.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CME achieves its forward estimates and maintains a stable P/E multiple of 22.1x. This scenario reflects the blended consensus of 37 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, CME Group Inc. (CME) has a Wall Street consensus price target of $299.00, based on estimates from 37 covering analysts. With the stock currently trading at $270.80, this represents a potential upside of +10.4%. The company has a market capitalization of $97.37B.
Analyst price targets range from a low of $260.00 to a high of $330.00, representing a 23% spread in expectations. The median target of $305.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Hold, with 14 analysts rating the stock as a Buy or Strong Buy,18 rating it Hold, and 5 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, CME trades at a trailing P/E of 24.3x and forward P/E of 22.1x. The forward PEG ratio of 1.61 indicates reasonable valuation for growth. Analysts expect EPS to grow +3.9% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $331.77, with bear and bull scenarios of $209.02 and $437.14 respectively. Model confidence stands at 53/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ICEIntercontinental Exchange, Inc. | $88.2B | $156.35 | $184.50 | +18.0% | Buy | 19.3x | 36 |
 CBOECboe Global Markets, Inc. | $28.1B | $268.87 | $317.00 | +17.9% | Hold | 19.2x | 31 |
 NDAQNasdaq, Inc. | $53.3B | $95.44 | $113.40 | +18.8% | Buy | 23.1x | 36 |
 MKTXMarketAxess Holdings Inc. | $5.8B | $163.71 | $142.50 | -13.0% | Hold | 20.6x | 24 |
 MSCIMSCI Inc. | $40.4B | $555.70 | $701.71 | +26.3% | Buy | 28.2x | 27 |
 SPGIS&P Global Inc. | $119.8B | $406.50 | $512.25 | +26.0% | Buy | 22.7x | 28 |
 FDSFactSet Research Systems Inc. | $9.9B | $279.43 | $256.75 | -8.1% | Hold | 15.7x | 30 |
 TWTradeweb Markets Inc. | $21.3B | $100.23 | $135.50 | +35.2% | Buy | 24.9x | 28 |
 BGCBGC Group, Inc | $5.7B | $12.10 | $11.50 | -5.0% | Buy | 8.6x | 2 |
 VIRTVirtu Financial, Inc. | $4.6B | $53.01 | $63.33 | +19.5% | Hold | 7.4x | 13 |
Quick answers to the most common questions about buying CME stock.
CME Group Inc. (CME) has a consensus 12-month price target of $299, implying 10.4% upside from $270.8. The 37 analysts covering CME see moderate appreciation potential.
CME has a consensus rating of "Hold" based on 37 Wall Street analysts. The rating breakdown is mixed, with 18 Hold ratings making up the largest segment. The consensus 12-month price target of $299 implies 10.4% upside from current levels.
CME trades at a forward P/E of 22.1067x, representing a moderate valuation. With analysts targeting $299 (10.4% implied move), the stock appears reasonably valued with upside.
The most bullish Wall Street analyst has a price target of $330 for CME, while the most conservative target is $260. The consensus of $299 represents the median expectation. Our quantitative valuation model projects a bull case target of $437 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
CME is heavily covered by Wall Street, with 37 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 14 have Buy ratings, 18 recommend Hold, and 5 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CME stock forecast based on 37 Wall Street analysts shows a consensus price target of $299, with estimates ranging from $260 (bear case) to $330 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $332, with bear/bull scenarios of $209/$437.
Our quantitative valuation model calculates CME's fair value at $332 (base case), with a bear case of $209 and bull case of $437. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 53/100.
CME trades at a forward P/E ratio of 22.1x based on next-twelve-months earnings estimates compared to a trailing P/E of 24.3x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are optimistic on CME, with a "Hold" consensus rating and $299 price target (10.4% upside). 14 of 37 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CME analyst price targets range from $260 to $330, a 23% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $299 consensus represents the middle ground. Our model's $209-$437 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.